Abstract: AZD9291 (Osimertinib) is a highly potent, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to target both EGFR-sensitizing mutations and the T790M resistance mutation while sparing wild-type EGFR. While osimertinib has demonstrated remarkable clinical efficacy as both a first- and second-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC), the emergence of acquired resistance remains an inevitable clinical challenge. This review comprehensively examines the pharmacological activity and structure-activity relationships of osimertinib, focusing heavily on the molecular mechanisms driving acquired resistance. These mechanisms are broadly categorized into EGFR-dependent (on-target) alterations, such as C797S, L718Q, and G724S mutations, and EGFR-independent (off-target) bypass signaling pathways, including MET and HER2 amplification, RAS/MAPK and PI3K/AKT pathway activation, oncogenic fusions, and histological transformations. Furthermore, this review highlights current limitations in overcoming tumor heterogeneity and discusses future perspectives, including the development of fourth-generation EGFR-TKIs, novel combination therapies, and the role of liquid biopsies in dynamic resistance monitoring.
1. Introduction
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases [5]. The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene revolutionized the therapeutic landscape, establishing EGFR tyrosine kinase inhibitors (TKIs) as the standard first-line treatment for EGFR-mutated advanced NSCLC [7]. However, despite the initial efficacy of first- and second-generation EGFR-TKIs (such as gefitinib, erlotinib, and afatinib), acquired resistance inevitably develops, most commonly driven by the EGFR T790M secondary "gatekeeper" mutation, which occurs in approximately 50% to 60% of cases [2][5].
To overcome this, osimertinib (AZD9291) was developed as a third-generation EGFR-TKI. It selectively and irreversibly inhibits both EGFR-TKI sensitizing mutations and the T790M resistance mutation [9]. Based on superior progression-free survival (PFS) and overall survival (OS) demonstrated in landmark clinical trials (such as AURA3 and FLAURA), osimertinib received approval for both second-line treatment in T790M-positive patients and first-line treatment for EGFR-mutated advanced NSCLC [5][9]. Nevertheless, acquired resistance to osimertinib eventually emerges, presenting a complex and heterogeneous molecular landscape that necessitates ongoing research into novel therapeutic strategies [8].
2. Pharmacological Activity
Osimertinib is an irreversible mono-anilino-pyrimidine EGFR TKI that covalently binds to the ATP-binding site of the EGFR tyrosine kinase domain [4]. Preclinical data indicate that osimertinib is approximately 200 times more potent against the L858R/T790M double mutation than against wild-type EGFR, which significantly minimizes the skin and gastrointestinal toxicities typically associated with wild-type EGFR inhibition [4][5]. Two circulating active metabolites, AZ5104 and AZ7550, also demonstrate comparable potency against sensitizing EGFR mutations and T790M [4].
Clinically, osimertinib exhibits remarkable efficacy. In the AURA3 trial, it demonstrated superiority over platinum-pemetrexed chemotherapy in T790M-positive patients [9]. In the first-line setting (FLAURA study), osimertinib significantly improved median PFS (18.9 vs. 10.2 months) and median OS (38.6 vs. 31.8 months) compared to standard first-generation EGFR-TKIs [9]. Furthermore, owing to its ability to penetrate the blood-brain barrier (BBB), osimertinib shows potent clinical activity against central nervous system (CNS) metastases, a common complication in advanced NSCLC [5][9].
3. Molecular Mechanism of Action
The molecular mechanisms of acquired resistance to osimertinib are highly heterogeneous and are broadly classified into EGFR-dependent (on-target) and EGFR-independent (off-target) mechanisms [8].
EGFR-Dependent (On-Target) Mechanisms: On-target resistance occurs in 10–20% of patients treated with first-line osimertinib [5]. The most common alteration is the C797S mutation, which accounts for 7–15% of resistance cases depending on the line of therapy [8]. Other rare tertiary mutations include alterations at the L718 (e.g., L718Q, L718V), L792 (e.g., L792H, L792V), and G796 (e.g., G796R, G796S, G796D) residues, as well as the G724S mutation [2][5]. Amplification of wild-type EGFR alleles has also been reported as a resistance mechanism [5]. Notably, in the second-line setting, loss of the T790M mutation is observed in nearly 50–68% of cases, often coinciding with the emergence of competing off-target resistance mechanisms [5][8].
EGFR-Independent (Off-Target) Mechanisms: Off-target mechanisms bypass EGFR signaling entirely and are more frequent than on-target mutations.
- MET Amplification: This is the most common off-target mechanism, occurring in 15–24% of patients progressing on osimertinib [5][8].
- HER2 Amplification: Detected in 2–5% of patients, HER2 directly activates downstream signaling to mediate resistance [5].
- Signaling Pathway Alterations: Activation of the RAS/MAPK and PI3K/AKT pathways is frequently observed. This includes KRAS (1–7%), NRAS, and BRAF V600E (3–4%) mutations, as well as PIK3CA mutations and PTEN loss [1][5].
- Cell Cycle Alterations: Alterations in cell cycle genes (e.g., CDK4/6, CDKN2A, Cyclin D1/E1) are found in 10–12% of resistant cases [5][8].
- Oncogenic Fusions: Fusions involving RET, ALK, BRAF, FGFR3, and NTRK1 act as bypass drivers in 1–10% of cases [5].
Histological and Phenotypic Transformations: Transformation from NSCLC to small cell lung cancer (SCLC) or squamous cell carcinoma occurs in 2–15% of patients and is strongly associated with concurrent inactivation of RB1 and TP53 [5][8]. Additionally, epithelial-mesenchymal transition (EMT), driven by factors like AXL activation, ZEB1, and TGFβ, is a recognized phenotypic resistance mechanism [1][2].
4. Structure-Activity Relationship (SAR)
The structure-activity relationship of osimertinib is defined by its ability to covalently bind to the cysteine residue at position 797 (Cys797) within the ATP-binding pocket of the EGFR kinase domain [4][5]. Acquired mutations directly disrupt this interaction through various structural mechanisms:
- C797X Mutations: The C797S mutation replaces the critical cysteine residue with a serine. Because serine lacks the reactive thiol group necessary for covalent bond formation, osimertinib can no longer irreversibly bind to the receptor, leading to profound drug resistance [5].
- L718 and L792 Mutations: Mutations at L718 (e.g., L718Q, L718V) and L792 (e.g., L792H, L792V) cause spatial restrictions. These residues are located in the ATP-binding site and the "hinge" region, respectively. Alterations here create steric hindrance that specifically interferes with the methoxy group of osimertinib, preventing it from properly docking into the kinase domain [2][5].
- Solvent Front Mutations (G796): Mutations at the G796 residue (G796R, G796S, G796D), which is adjacent to C797, sterically interfere with the osimertinib-EGFR interaction. Structural modeling shows that G796R has a major impact on binding affinity [2].
- G724S Mutation: Structural analyses and computational modeling indicate that the G724S mutation induces a conformational change in the kinase domain that is structurally incompatible with the binding of third-generation TKIs like osimertinib [5].
5. Current Limitations
Despite the success of osimertinib, several limitations persist in the clinical management of EGFR-mutated NSCLC. The most significant limitation is the inevitability of acquired resistance. The resistance landscape is characterized by extreme spatiotemporal tumor heterogeneity; it is common for multiple resistance mechanisms (e.g., MET amplification alongside C797S) to co-exist within different subclones of the same tumor [5][8]. Furthermore, the loss of the T790M mutation during osimertinib therapy often leads to the emergence of diverse, off-target competing mechanisms, complicating subsequent treatment choices [5].
Preclinical models also present limitations. While cell lines are useful for studying mechanisms like MET amplification or EMT, they fail to recapitulate certain clinical phenomena. For instance, SCLC transformation is frequently observed in clinical tissue biopsies but has not been successfully modeled in vitro in osimertinib-resistant cell lines [1]. Finally, while combination therapies targeting bypass pathways (e.g., combining osimertinib with MEK or JAK inhibitors) show preclinical promise, they often result in overlapping toxicity profiles in patients, limiting their clinical tolerability and feasibility [5].
6. Future Perspectives
To address osimertinib resistance, future therapeutic strategies are heavily focused on the development of next-generation inhibitors and rational combination therapies.
Fourth-Generation EGFR-TKIs: Novel compounds are being developed to target the C797S mutation. Allosteric inhibitors like EAI045 bind to a non-ATP competitive site and show efficacy against L858R/T790M/C797S mutants when combined with cetuximab [3]. Other fourth-generation TKIs in clinical development, such as BLU-945 and JBJ-04-125-02, have demonstrated potent preclinical and early clinical activity against triple-mutant EGFR signaling [5][8].
Combination Therapies: Co-targeting EGFR and bypass pathways is a major focus. Clinical trials (e.g., TATTON, SAVANNAH) are evaluating osimertinib in combination with MET inhibitors (savolitinib, crizotinib) for MET-amplified tumors [1][8]. Combinations with MEK inhibitors (selumetinib, trametinib) for RAS/MAPK alterations, and CDK4/6 inhibitors (palbociclib, abemaciclib) for cell cycle dysregulation, are also under active investigation [5]. Additionally, the FLAURA-2 trial is exploring the upfront combination of osimertinib with platinum-based chemotherapy to delay the onset of resistance [8].
Liquid Biopsies and Precision Medicine: The dynamic monitoring of circulating tumor DNA (ctDNA) via next-generation sequencing (NGS) is becoming essential. Liquid biopsies allow for the real-time identification of emerging resistance clones (e.g., C797S, MET amplification, or oncogenic fusions) without invasive tissue biopsies, enabling oncologists to tailor subsequent therapies to the evolving molecular profile of the tumor [2][8].
